---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-25-000108"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:57:50.567044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025

## Summary
- Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.
- Sold REV102 to Recursion for up to $25M, including $7.5M upfront equity; cash runway extended into mid-2027.
- RLYB116 confirmatory PK/PD study dosing started; Cohort 1 and Cohort 2 topline data expected Q3 and Q4 2025.
- RLYB212 program discontinued after Phase 2 PK data missed target concentrations.
- Cash, equivalents and marketable securities $45.7M at June 30, 2025; with REV102 payment, runway into mid-2027.

## SEC filing metadata
- accession: 0001739410-25-000108
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/0001739410-25-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/rlyb-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-25-000108
- JSON: https://secwatch.observer/filing/0001739410-25-000108.json
- Plain text: https://secwatch.observer/filing/0001739410-25-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.